Article
- The EMBO Journal (2002) 21, 665 - 674
- doi:10.1093/emboj/21.4.665
Subject Category:
Oncogenic potential of a C.elegans cdc25 gene is demonstrated by a gain-of-function allele
Caroline Clucas1, Juan Cabello2, Ingo Büssing2, Ralf Schnabel2 and Iain L. Johnstone1
- The Wellcome Centre for Molecular Parasitology, The University of Glasgow, Anderson College, 56 Dumbarton Road, Glasgow, UK
- Institut für Genetik, TU Carolo Wilhelmina, Spielmann Strasse 7, D-38106 Braunschweig, Germany
Correspondence to:
Iain L. Johnstone, E-mail: i.johnstone@vet.gla.ac.uk
Received 8 November 2001; Accepted 12 December 2001; Revised 12 December 2001
Abstract
In multicellular organisms, developmental programmes must integrate with central cell cycle regulation to co-ordinate developmental decisions with cell proliferation. Hyperplasia caused by deregulated proliferation without significant change to other aspects of developmental behaviour is a probable step towards full oncogenesis in many malignancies. CDC25 phosphatase promotes progression through the eukaryotic cell cycle by dephosphorylation of cyclin-dependent kinase and, in humans, different cdc25 family members have been implicated as potential oncogenes. Demonstrating the direct oncogenic potential of a cdc25 gene, we identify a gain-of-function mutant allele of the Caenorhabditis elegans gene cdc-25.1 that causes a deregulated proliferation of intestinal cells resulting in hyperplasia, while other aspects of intestinal cell function are retained. Using RNA-mediated interference, we demonstrate modulation of the oncogenic behaviour of this mutant, and show that a reduction of the wild-type cdc-25.1 activity can cause a failure of proliferation of intestinal and other cell types. That gain and loss of CDC-25.1 activity has opposite effects on cellular proliferation indicates its critical role in controlling C.elegans cell number.
Keywords:
- cdc25,
- cell cycle,
- C.elegans,
- development,
- oncogene



